AI주식인사이트AI Stock Insight
B

셀바이오휴먼텍

318160KOSDAQ

65.5 / 100

Reference Date: 2026-10-23

Financial Score36.0 / 40
News Sentiment12.5 / 25
Momentum5.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health and PER is significantly undervalued vs. peers is also solid. Declined 8.7% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

CellbiohumanTek, established in 2015, specializes in developing and manufacturing eco-friendly cellulose-based mask sheet materials. Its key products include biodegradable and vegan-certified materials like PT CELL and SEMI GEL, with expansion into medical fields such as hydrocolloid wound dressings. The company operates a non-woven fabric production plant in Vietnam to reduce reliance on imports and enhance cost efficiency and quality.

Number of Employees

97people

Average Salary

58.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
6.08Industry Average 15.008.0Point

Half of industry avg (excellent)

PBR
1.03Industry Average 1.204.0Point

In line with industry avg

ROE
16.50Industry Average 8.007.0Point

2.1x industry avg (excellent)

Debt Ratio
17.38Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20259.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲41.9% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲79.5% (2-year basis)

ROE Trend
3.0 / 4

Avg ROE 7.1% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (21%)

Current 6,440Won52-week high 10,56052-week low 5,340
1-month return1.0Point

1m -8.65% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 1Neutral 1Negative 0
  • Neutral신탁계약해지결과보고서2026-10-21
  • Positive주요사항보고서(자기주식취득신탁계약해지결정)2026-10-21